CLRB

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2010, for Novelos Therapeutics, Inc. (now operating as Cellectar Biosciences, Inc. following a business combination). The filing details a strategic pivot: on April 8, 2011, Novelos completed a reverse merger with Cellectar, Inc. As a result, Novelos suspended development of its legacy oxidized glutathione-based compounds (NOV-002 and NOV-205) and adopted Cellectar's cancer-targeting technology platform. The company is now focused on three primary candidates: CLR1401 ("COLD"), 131I-CLR1404 ("HOT"), and 124I-CLR1404 ("LIGHT").

Key Financial Metrics

Note: The 2010 Net Income was driven by a non-cash gain of $8.1 million on derivative warrants due to a decline in stock price. The company reported a Net Loss attributable to common stockholders of $12.7 million after preferred stock dividends and deemed dividends.

Material Changes vs. Prior Period

• Revenue: Remained flat at approximately $33,000, derived solely from the amortization of license fees from a collaboration with Lee's Pharm.
• R&D Expenses: Decreased by 63% ($5.1 million) compared to 2009. This reduction was primarily due to the completion of the Phase 3 trial for NOV-002 in February 2010, which eliminated significant contract research costs.
• Derivative Warrants: The company recorded a gain of $8.1 million in 2010, reversing a loss of $12.1 million in 2009. This fluctuation reflects changes in the fair value of warrants with "down-round" provisions following the stock price drop after the failed Phase 3 trial.
• Capital Structure: In November 2010, all outstanding Series C and Series E preferred stock (including accrued dividends totaling ~$4.5 million) was exchanged for common stock, eliminating the preferred stock liquidation preference.

Guidance, Outlook, and Risks

Outlook and Guidance: Management believes cash on hand ($2.4 million at year-end) plus proceeds from a concurrent April 2011 private placement ($5.1 million) is sufficient to fund operations into the fourth quarter of 2011. The company expects to continue generating operating losses for the foreseeable future and will require additional capital to execute its operating plan beyond late 2011.

Development Pipeline:

• HOT (131I-CLR1404): Phase 1b dose-escalation trial expected to begin in Q3 2011; Phase 2 efficacy trials expected in 2012.
• LIGHT (124I-CLR1404): Investigator-sponsored Phase 1/2 trials expected to begin mid-2011.
• COLD (CLR1401): IND application expected in late 2012.

Risks and Contingencies:

• Going Concern: Auditors have expressed substantial doubt about the company's ability to continue as a going concern without additional capital.
• Litigation: A class action lawsuit is pending regarding disclosures related to the failed Phase 3 trial of NOV-002. Additionally, a dispute exists with ZAO BAM regarding intellectual property rights to NOV-002.
• Regulatory: Success depends on obtaining FDA approvals, which are uncertain and costly.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $7.5 million total cash position (year-end cash + April 2011 proceeds) to fund operations through Q4 2011.
• Derivative Liability: Confirm the remaining fair value of derivative warrant liabilities ($288,250 at year-end) and potential future volatility impact on earnings.
• Legal Exposure: Monitor the status of the shareholder class action lawsuit and the ZAO BAM intellectual property dispute.
• Capital Needs: Assess the timeline and terms for the necessary equity or debt financing required post-Q4 2011.
• Merger Integration: Evaluate the progress of the integration of Cellectar's operations and the suspension of Novelos's legacy pipeline.